Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial
Open Access
- 1 August 2000
- journal article
- clinical trial
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 69 (2), 217-221
- https://doi.org/10.1136/jnnp.69.2.217
Abstract
OBJECTIVES After stroke, abnormal arm posture due to spasticity in a functionally useless arm may interfere with self care tasks. In these patients botulinum toxin treatment presents an opportunity to reduce disability. The purpose was to investigate whether reduction in spasticity after botulinum toxin treatment translates into reduction in disability and carer burden. METHODS Forty patients with stroke with spasticity in a functionally useless arm (median duration 3.1 years) were randomised to receive intramuscular botulinum toxin type A (BT-A; Dysport) (n=20) or placebo (n=20) in a total dose of 1000 MU divided between elbow, wrist, and finger flexors. Spasticity (using the modified Ashworth scale), muscle power, joint movement, and pain were assessed. Disability and carer burden were measured using an eight item and a four item scale respectively. Two baseline and three post-treatment assessments (weeks 2, 6, and 12) were made. Concurrent treatments as far as possible remained unchanged and not optimised. RESULTS Disability improved at week 6 with BT-A compared with placebo. This effect, present at week 2, wore off by week 12. Reduction in carer burden was seen at week 6 with BT-A and continued for at least 12 weeks. Forearm flexor spasticity was reduced with BT-A up to 12 weeks after treatment. Although significant improvement in elbow flexor spasticity was seen at week 2 with BT-A compared with placebo, this effect was not evident at weeks 6 and 12. Arm pain was not improved after BT-A. Grip strength was reduced with BT-A. No serious BT-A related adverse effects were reported. CONCLUSION BT-A is useful for treating patients with stroke who have self care difficulties due to arm spasticity. The decision to treat should also include relief of carer burden. As muscle weakness may occur, its potential impact on functional activities must be assessed before intervention.Keywords
This publication has 14 references indexed in Scilit:
- Botulinum toxin type A in the treatment of upper extremity spasticityNeurology, 1996
- Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patientsNeuroscience Letters, 1995
- Treatment of chronic limb spasticity with botulinum toxin A.Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Recovery of upper extremity function in stroke patients: The Copenhagen stroke studyArchives of Physical Medicine and Rehabilitation, 1994
- Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25Nature, 1993
- Effect of treatment with botulinum toxin on spasticityPostgraduate Medical Journal, 1989
- A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86. 1. Methodology, demography and incident cases of first-ever stroke.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- Functional assessment of the hand: reproducibility, acceptability, and utility of a new system for measuring strength.Annals Of The Rheumatic Diseases, 1987
- Interrater Reliability of a Modified Ashworth Scale of Muscle SpasticityPTJ: Physical Therapy & Rehabilitation Journal, 1987
- FUNCTIONAL EVALUATION: THE BARTHEL INDEX.1965